spot_img
Wednesday, June 22, 2022
More
    HomeHealthSTAT+: FDA removes clinical hold on cancer studies of Allogene off-the-shelf CAR-T...

    STAT+: FDA removes clinical hold on cancer studies of Allogene off-the-shelf CAR-T treatment

    -



    Allogene mentioned Monday that medical trials involving its off-the-shelf CAR-T therapies for blood most cancers are resuming following a security clearance by U.S. regulators.

    In October, the Meals and Drug Administration positioned five Allogene studies on hold after a single handled affected person was discovered to have a “chromosomal abnormality.” However a three-month investigation carried out by Allogene concluded its CAR-T referred to as ALLO-501A was not answerable for the chromosomal abnormality, and that it had no medical significance for the affected person.

    Continue to STAT+ to read the full story…



    Source link

    Related articles

    Stay Connected

    0FansLike
    0FollowersFollow
    3,357FollowersFollow
    0SubscribersSubscribe
    spot_img

    Latest posts